All articles by GlobalData Healthcare

Real-world analysis links sleep apnoea to heightened risk of glaucoma

Obstructive sleep apnoea (OSA) is a condition characterised by repeated cessation of breathing during sleep, caused by collapse of the…
ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering

This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety and…
ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression

During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic (T1D)…
Study explores gaps in Europe’s steatotic liver disease response plans

The growing prevalence of metabolic dysfunction-associated steatotic liver disease and non-alcoholic steatotic hepatitis (MASLD/NASH) poses a growing public health risk,…
ADA26: Kidney disease analysis given spotlight

At this year’s American Diabetes Association (ADA) congress, while obesity and diabetes treatments took the limelight, there were sessions focused…

ASCO 2026: darovasertib raises the bar in metastatic uveal melanoma

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, held on 29 May - 2 June, primary results…
ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies

Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at…
ASCO 2026: Novel CD5 directed CAR-T therapy for T-ALL/PTCL shows mixed response

Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma (PTCL) represent a group with…
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer

At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was…
ASCO 2026: Monjuvi to rival Polivy in 1L DLBCL after strong Phase III results

Treatment of refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) has seen major advances in recent years, with the…